Esta página aún no está traducida al español y se muestra en inglés. Estamos trabajando en su traducción.

Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

NAD+ and Its Precursors: What the Human Trials Report

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 9 de noviembre de 2026

ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso estético tópico a clínicas con licencia, y trabaja con una farmacia de preparados compuestos 503A que prepara formulaciones para prescriptores con licencia según prescripciones individuales.

Qué cubre esta página, quién puede comprar a ExaVeyra, y qué se suministra
PreguntaRespuesta
Qué cubre esta páginaNAD+ injection evidence: what the human trials of nicotinamide riboside, NMN and intravenous NAD+ report, plus the FDA record on NMN and compounded NAD+.
Quién puede hacer pedidosClínicas y profesionales con licencia profesional activa y NPI verificados por ExaVeyra. Los pedidos de exosomas requieren además un reconocimiento firmado de uso profesional.
Qué se envía y cómoLas formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual del profesional con licencia, y se envían desde la farmacia. Las sustancias controladas las dispensa la farmacia con su propio registro de la DEA.

The human evidence for NAD+ comes almost entirely from oral precursor trials. A 2026 PRISMA-guided systematic review of 113 studies, 33 of them in humans, reported that oral nicotinamide riboside and nicotinamide mononucleotide "consistently demonstrated biochemical target engagement" and "were generally well tolerated over weeks to months", while effects on functional, metabolic and vascular outcomes "were heterogeneous and often null or endpoint-specific".[1] The same review found that "No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications".[1] The one controlled intravenous pilot infused NAD+ into eight men over six hours and detected no change in plasma NAD+ or its metabolites until after the second hour.[2]

NAD+ is a redox coenzyme and a substrate for sirtuins, PARPs and CD38

Nicotinamide adenine dinucleotide cycles between an oxidized form, NAD+, and a reduced form, NADH, carrying electrons through glycolysis, the citric acid cycle and the respiratory chain.[3] The NIH Office of Dietary Supplements states that "More than 400 enzymes require NAD to catalyze reactions in the body, which is more than for any other vitamin-derived coenzyme", and that NAD is also converted to NADP, which "enables anabolic reactions, such as the synthesis of cholesterol and fatty acids".[4] A second set of enzymes consumes NAD+ rather than recycling it: the 2021 review by Covarrubias and colleagues describes NAD+ as "an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases", records that "ageing is accompanied by a gradual decline in tissue and cellular NAD+ levels in multiple model organisms, including rodents and humans", and adds that it remains to be learned "how to effectively restore NAD+ levels during ageing, whether doing so is safe and whether NAD+ repletion will have beneficial effects in ageing humans".[3]

The CD38 finding is preclinical. Camacho-Pereira and colleagues reported in 2016 that CD38 activity increases with aging in mice, that CD38 "is required for the age-related NAD decline and mitochondrial dysfunction", and that it is "the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo".[5] The precursors sit upstream: niacin is "the generic name for nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (niacinamide or pyridine-3-carboxamide), and related derivatives, such as nicotinamide riboside", and "When NAD and NADP are consumed in foods, they are converted to nicotinamide in the gut and then absorbed".[4] The human trials accordingly test the precursors nicotinamide riboside and nicotinamide mononucleotide and measure NAD+ metabolites in blood or tissue.[1]

The cited oral precursor trials reported a rise in NAD+ metabolites

The largest nicotinamide riboside trial cited here enrolled 140 healthy overweight adults in an eight-week randomized, double-blind, placebo-controlled study of three NR amounts against placebo, funded by the ingredient's manufacturer; it reported that NR "dose-dependently and significantly increased whole blood NAD+" within two weeks, with the increases "maintained throughout the remainder of the study".[6] Martens and colleagues randomized 30 healthy middle-aged and older adults to a crossover of two six-week periods and reported that chronic NR "is well tolerated and effectively stimulates NAD+ metabolism".[7] For nicotinamide mononucleotide, Yi and colleagues randomized 80 healthy middle-aged adults to placebo or one of three daily oral NMN amounts for 60 days, in a trial fully funded by two NMN manufacturers that employ three of its authors, and reported blood NAD "statistically significantly increased among all NMN-treated groups at day 30 and day 60".[8] In 12 aged men, Elhassan and colleagues reported that NR "elevated the muscle NAD+ metabolome" and that "oral NR is available to aged human muscle", "without altering mitochondrial bioenergetics".[9]

TrialDesign and participantsPopulationWhat the authors reported
Conze 2019Randomized, double-blind, placebo-controlled, parallel; 140 enrolledHealthy overweight adultsWhole blood NAD+ rose with each NR amount within two weeks and stayed elevated; no flushing; no difference in adverse events
Martens 2018Randomized, double-blind, placebo-controlled crossover; 30 randomizedHealthy middle-aged and older adultsNR well tolerated and stimulated NAD+ metabolism; 14 mild treatment-emergent adverse events in 7 of 30 participants
Yi 2023Randomized, multicenter, double-blind, placebo-controlled, parallel; 80Healthy middle-aged adultsBlood NAD rose in every NMN group; walking distance higher than placebo; biological age score unchanged against a rise on placebo
Elhassan 2019Randomized, double-blind, placebo-controlled crossover; 12Aged menMuscle NAD+ metabolome elevated; inflammatory cytokines lower; mitochondrial bioenergetics unchanged
Dollerup 2018Randomized, double-blind, placebo-controlled, parallel; 40Men with obesity and insulin resistanceNo improvement in insulin sensitivity, glucose metabolism, energy expenditure or body composition; no serious adverse events
Yoshino 2021Randomized, double-blind, placebo-controlled; 25 completedPostmenopausal women with prediabetes who were overweight or obeseInsulin-stimulated glucose disposal and muscle insulin signaling increased after NMN and not after placebo
Brakedal 2022 (NADPARK)Randomized, double-blinded phase I; 30Newly diagnosed, treatment-naive Parkinson disease populationCerebral NAD rose, with variability, on MR spectroscopy; inflammatory cytokines fell; well tolerated

Functional and metabolic outcomes were mixed or null across the precursor trials

The biochemical signal did not translate into a consistent clinical one. Dollerup and colleagues randomized 40 sedentary men with obesity and insulin resistance to twelve weeks of NR or placebo and reported that "Insulin sensitivity, endogenous glucose production, and glucose disposal and oxidation were not improved by NR supplementation", with no effect on energy expenditure, lipolysis or body composition.[10] Yoshino and colleagues, in a ten-week randomized placebo-controlled trial completed by 25 postmenopausal women with prediabetes who were overweight or obese, reported the opposite direction for NMN: insulin-stimulated glucose disposal and muscle insulin signaling "increased after NMN supplementation but did not change after placebo treatment".[11] A 2024 meta-analysis of eight randomized NMN trials in 342 middle-aged and older adults "indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile".[12] In the Yi trial, six-minute walking distance increased more in every NMN group than on placebo, and a blood-based biological age score rose on placebo while staying unchanged on NMN, alongside no change in HOMA-IR.[8]

The NADPARK phase I trial enrolled 30 newly diagnosed, treatment-naive patients in a Parkinson disease population and reported that NR "led to a significant, but variable, increase in cerebral NAD levels" on phosphorus magnetic resonance spectroscopy, altered cerebral metabolism on PET "associated with mild clinical improvement" in those whose brain NAD rose, and lower inflammatory cytokines; the authors call for "further investigation in larger trials", and two of them hold a patent application on the use.[13] Across the whole literature, the 2026 systematic review concluded that "NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive".[1]

Intravenous NAD+ has one pharmacokinetic pilot and no outcome trials

Compounded NAD+ given by injection or infusion is a different molecule on a different route from the oral precursors, and the controlled data are correspondingly thin. Grant and colleagues recruited eleven healthy men aged 30 to 55, randomized eight to a six-hour intravenous NAD+ infusion and three to saline, and reported that "no change in plasma (NAD+) or metabolites" was observed "until after 2 h", that NAD+ "is rapidly and completely removed from the plasma for at least the first 2 h", and that urinary excretion of NAD+ and methylnicotinamide rose by six hours; they describe it as the first data "on the fate of directly infused NAD+ in a human cohort".[2] Two of the authors are affiliated with an NAD+ research company and the wellness center that delivered the infusions.[2] The 2026 systematic review found no eligible outcome trial of intravenous or intramuscular NAD+ and called for larger randomized trials "particularly for parenteral approaches".[1] One randomized comparison is registered: NCT06919328, sponsored by the Nutraceuticals Research Institute with an industry collaborator, compares injectable nicotinamide riboside with NAD+ and a bacteriostatic water placebo in healthy adults, lists 70 estimated participants, and was recruiting at its last update posted on 9 April 2025, with no result posted as of 8 November 2026.[14]

What the trials and the fact sheet report on safety

Adverse event reporting in the precursor trials was consistent. Conze and colleagues recorded "no reports of flushing and no significant differences in adverse events between the NR and placebo-treated groups", and that NR "did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism".[6] Martens and colleagues reported 14 treatment-emergent adverse events from 7 of 30 participants, all mild, with both side-effect withdrawals occurring in the placebo phase.[7] Dollerup and colleagues observed "No serious adverse events due to NR supplementation", and Yi and colleagues found "No safety issues, based on monitoring adverse events (AEs), laboratory and clinical measures".[8][10] For the parent vitamin, the Office of Dietary Supplements states that nicotinic acid "in supplemental amounts beyond nutritional needs can cause skin flushing", that "Nicotinamide does not produce skin flushing because of its slightly different chemical structure", that high intakes of nicotinic acid over months or years "can also be hepatotoxic", and that the Tolerable Upper Intake Level for supplemental niacin "does not apply to individuals who are receiving supplemental niacin under medical supervision".[4] The fact sheet makes no safety statement specific to injectable NAD+.[4] The intravenous pilot was designed to measure pharmacokinetics; its authors reported that no adverse events were observed during the six-hour infusion in either the NAD+ or the saline group, a finding from eight infused participants.[2]

FDA excluded NMN from the dietary supplement definition in 2022 and reversed that position in 2025

In letters dated 11 October 2022 and 4 November 2022 responding to new dietary ingredient notification 1259 for beta-nicotinamide mononucleotide, FDA's Center for Food Safety and Applied Nutrition determined that NMN "was not marketed as a dietary supplement, except unlawfully without an NDI notification, or as a food before FDA authorized it for investigation as a new drug", and concluded "that NMN is excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B)(ii) and may not be marketed as or in a dietary supplement."[15] The letters cite registered trials of an NMN drug candidate as the public investigations.[15]

The Office of Dietary Supplements fact sheet, last updated 18 November 2022, records the 2022 position: "FDA ruled in November 2022 that NMN may not be legally marketed as a dietary supplement because it has been authorized for investigation by FDA as a new drug."[4] FDA revisited that determination on 29 September 2025 in response to a citizen petition from the Natural Products Association and the Alliance for Natural Health USA. Having determined that "the first marketing of NMN as a dietary supplement in the United States preceded the authorization of NMN for investigation as a new drug", the agency concluded that "NMN is not excluded from the dietary supplement definition under section 201(ff)(3)(B)."[16]

Compounded NAD+ sits in category 1 of the FDA 503A bulk substances list

Section 503A(b)(1)(A) permits compounding with bulk drug substances that comply with "an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists", or "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary", or otherwise "appear on a list developed by the Secretary through regulations", provided they are made by a registered establishment and "are accompanied by valid certificates of analysis for each bulk drug substance".[17] The codified list at 21 CFR 216.23, as published on the eCFR for 5 November 2026, names six substances and none of them is NAD+.[18]

FDA's category PDF, updated 14 May 2026, places "Nicotinamide Adenine Dinucleotide (NAD)" and "Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH)" in category 1, "Bulk Drug Substances Under Evaluation", and places "Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate" in category 3, "Bulk Drug Substances Nominated Without Adequate Support".[19] FDA's bulk substances page, current as of the same date, states that the agency "will continue to evaluate sufficiently supported nominations for inclusion on the 503A bulks list in accordance with the process and criteria described in the FD&C Act".[20]

FDA's compounding questions and answers page states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."[21] The same page says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug".[21]

What the sources leave for a practice to document

The sources describe a precursor literature that reliably raises NAD+ metabolites with mixed downstream outcomes, and an injectable literature of one pharmacokinetic pilot and one recruiting trial.[1][2][14] The documents a practice would hold follow from the statute and the agency pages.[17][21]

  • The pharmacy's certificate of analysis for the bulk NAD+, which section 503A(b)(1)(A)(iii) requires to accompany each bulk drug substance.
  • The patient-specific prescription on which the 503A pharmacy compounded the preparation, since the exemption in section 503A applies only to a drug compounded for an identified individual patient.
  • A note of which FDA category the salt the pharmacy sources sits in on the date of dispensing, because the category PDF changes.
  • Patient counseling consistent with FDA's statement that compounded drugs are not FDA approved.

ExaVeyra's NAD+ reaches a practice through its licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis available for each lot; the catalog listing is at /products/small-molecules/nad-plus. Whether to use the compound, in which patients, by which route, and with what monitoring are decisions for the prescribing practitioner.[17][21]

This article summarizes published human studies and publicly available federal records for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Referencias comentadas

Numeradas en el orden en que se citan en el texto. Cada fuente lleva una nota sobre lo que respalda en esta página; los artículos revisados por pares se listan con revista, volumen, número y páginas, y las fuentes primarias son regulaciones, documentos de agencias, guías y declaraciones de posición.

  1. 1.Peer-reviewedGallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. https://pubmed.ncbi.nlm.nih.gov/41655607/Annotation: The 2010 to 2025 systematic review of 113 studies: consistent biochemical target engagement with oral NR and NMN, heterogeneous or null outcomes, and no eligible outcome trial of intravenous or intramuscular NAD+.
  2. 2.Peer-reviewedGrant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in Aging Neuroscience. 2019;11:257. https://pubmed.ncbi.nlm.nih.gov/31572171/Annotation: The controlled intravenous NAD+ pharmacokinetic pilot: eight men infused and three saline controls; no plasma change until after two hours; urinary NAD+ and methylnicotinamide at six hours; no adverse events observed during the infusion.
  3. 3.Peer-reviewedCovarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. https://pubmed.ncbi.nlm.nih.gov/33353981/Annotation: NAD+ as a redox coenzyme and as a cofactor for sirtuins, CD38 and PARPs; the reported age-related decline; the authors' statement of what remains unknown about restoring NAD+ in humans.
  4. 4.Official sourceNIH Office of Dietary Supplements, Niacin: Fact Sheet for Health Professionals (updated 18 November 2022). Accessed 8 November 2026. https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
  5. 5.Peer-reviewedCamacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/Annotation: The mouse finding that CD38 activity rises with age, is required for the age-related NAD decline, and is the main enzyme degrading NMN in vivo.
  6. 6.Peer-reviewedConze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. 2019;9(1):9772. https://pubmed.ncbi.nlm.nih.gov/31278280/Annotation: The largest NR trial cited on this page: whole blood NAD+ rose with each amount within two weeks; no flushing; no adverse event difference against placebo; manufacturer funded.
  7. 7.Peer-reviewedMartens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/Annotation: The crossover trial in healthy middle-aged and older adults: NAD+ metabolism stimulated, tolerability, and the adverse event tally of 14 mild events in 7 of 30 participants.
  8. 8.Peer-reviewedYi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. https://pubmed.ncbi.nlm.nih.gov/36482258/Annotation: The 60-day NMN trial: blood NAD rose in every NMN group; walking distance and a blood biological age score as the authors reported them; no safety issues; fully funded by two NMN manufacturers that employ three of its authors.
  9. 9.Peer-reviewedElhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. 2019;28(7):1717-1728.e6. https://pubmed.ncbi.nlm.nih.gov/31412242/Annotation: Oral NR reached aged human muscle and raised its NAD+ metabolome, lowered circulating inflammatory cytokines, and left mitochondrial bioenergetics unchanged.
  10. 10.Peer-reviewedDollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition. 2018;108(2):343-353. https://pubmed.ncbi.nlm.nih.gov/29992272/Annotation: The null metabolic result: twelve weeks of NR did not improve insulin sensitivity, glucose metabolism, energy expenditure or body composition in men with obesity and insulin resistance; no serious adverse events.
  11. 11.Peer-reviewedYoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/Annotation: The positive metabolic result: insulin-stimulated glucose disposal and muscle insulin signaling increased after ten weeks of NMN in postmenopausal women with prediabetes who were overweight or obese.
  12. 12.Peer-reviewedChen F, Zhou D, Kong AP, Yim NT, Dai S, Chen YN, Hui LL. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 2024;25(1):4. https://pubmed.ncbi.nlm.nih.gov/39531138/Annotation: Eight randomized NMN trials pooled: no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile.
  13. 13.Peer-reviewedBrakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 2022;34(3):396-407.e6. https://pubmed.ncbi.nlm.nih.gov/35235774/Annotation: The phase I trial in a newly diagnosed Parkinson disease population: variable rise in cerebral NAD on MR spectroscopy, lower inflammatory cytokines, tolerability, and the authors' call for larger trials.
  14. 14.Official sourceClinicalTrials.gov, NCT06919328, Absorption and Tolerability of Injectable Administration of Niagen+, as Compared to NAD+ (Nutraceuticals Research Institute; recruiting, last update posted 9 April 2025). Accessed 8 November 2026. https://clinicaltrials.gov/study/NCT06919328
  15. 15.RegulatoryFDA Center for Food Safety and Applied Nutrition, letters to Inner Mongolia Kingdomway Pharmaceutical Limited regarding NDI 1259, beta-Nicotinamide Mononucleotide (11 October 2022 and 4 November 2022), docket FDA-2022-S-0023, document 0051 (regulations.gov). Accessed 8 November 2026. https://www.regulations.gov/document/FDA-2022-S-0023-0051
  16. 16.RegulatoryFDA Human Foods Program, response letter to the Natural Products Association and Alliance for Natural Health USA, citizen petition docket FDA-2023-P-0872, document 2754 (posted 29 September 2025), regulations.gov. Accessed 9 November 2026. https://www.regulations.gov/document/FDA-2023-P-0872-2754
  17. 17.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
  18. 18.Regulatory21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, current through 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
  19. 19.RegulatoryFDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1, 2 and 3), PDF updated 14 May 2026. Accessed 8 November 2026. https://www.fda.gov/media/94155/download
  20. 20.RegulatoryFDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 14 May 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  21. 21.RegulatoryFDA, Compounding and the FDA: Questions and Answers (content current as of 16 September 2025). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Cite this page

ExaVeyra Sciences Editorial Team. NAD+ and Its Precursors: Human Trials. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/nad-plus-and-precursors-human-trials. Accessed [date accessed].

Recursos exclusivos para miembros de ExaVeyra

Para prácticas verificadas y aprobadasReservado para profesionales clínicos

Bóveda de investigación

Literatura revisada por pares seleccionada para cada compuesto del catálogo, con un resumen imprimible de dos minutos, la evidencia de un vistazo y los artículos por los que empezar.

  • 266 artículos revisados por pares, cada uno con su enlace DOI o PubMed
  • 8 áreas de investigación
  • 128 revisiones sistemáticas, metaanálisis y ensayos aleatorizados
  • 18 compuestos con un resumen de dos minutos

El registro toma unos dos minutos. El acceso se habilita tras la verificación del NPI y una revisión de nuestro equipo. No se piden datos de pago.

Cada resumen empieza por los diseños de estudio más sólidos y luego los más recientes.

Preguntas frecuentes

Is there a controlled human trial of intravenous NAD+?
As of 8 November 2026 the published controlled data consist of one pharmacokinetic pilot, Grant 2019, in which eight healthy men received a six-hour NAD+ infusion and three received saline; it reported no change in plasma NAD+ or its metabolites until after the second hour and did not measure clinical outcomes. A 2026 systematic review found no eligible outcome trial of intravenous or intramuscular NAD+. One randomized comparison of injectable nicotinamide riboside against NAD+ and placebo, NCT06919328, was recruiting at its last update.
What do the oral nicotinamide riboside and NMN trials report?
The cited trials that measured it reported that oral NR or NMN raised NAD+ or its metabolites in blood, and in Elhassan 2019 in muscle, over weeks to months, and a 2026 systematic review describes this biochemical effect as consistent; the trials reported the precursors as well tolerated. Functional and metabolic outcomes were mixed: Dollerup 2018 found no change in insulin sensitivity in men with obesity, Yoshino 2021 found increased muscle insulin sensitivity in postmenopausal women with prediabetes, and a 2024 meta-analysis of eight NMN trials found no significant effect on glucose or lipid markers.
Why do researchers study precursors rather than oral NAD+?
The NIH Office of Dietary Supplements states that when NAD and NADP are consumed in foods they are converted to nicotinamide in the gut and then absorbed. The human trials test precursors such as nicotinamide riboside and NMN, and a 2026 systematic review reported that oral NR and NMN consistently raised NAD-related metabolites in blood or cells.
What is FDA's position on NMN as a dietary supplement?
In letters dated 11 October and 4 November 2022 responding to new dietary ingredient notification 1259, FDA concluded that NMN was excluded from the dietary supplement definition under 21 U.S.C. 321(ff)(3)(B)(ii). On 29 September 2025, responding to a citizen petition, FDA revised its reading of the statute and concluded that NMN is not excluded from the dietary supplement definition, because NMN was first marketed as a dietary supplement in the United States before it was authorized for investigation as a new drug. The NIH niacin fact sheet, last updated 18 November 2022, still records the 2022 ruling.
Where does NAD+ sit on the FDA compounding lists?
The codified 503A bulks list at 21 CFR 216.23 does not include NAD+. FDA's category PDF updated 14 May 2026 lists Nicotinamide Adenine Dinucleotide (NAD) and the reduced disodium salt (NADH) in category 1, bulk drug substances under evaluation, and lists Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate in category 3, nominated without adequate support. Categories change, so a practice checks the current PDF on the date of dispensing.
What safety findings did the trials report?
Conze 2019 reported no flushing and no difference in adverse events between NR and placebo in 140 adults; Martens 2018 reported 14 mild treatment-emergent adverse events in 7 of 30 participants, with both side-effect withdrawals occurring on placebo; Dollerup 2018 and Yi 2023 reported no serious adverse events or safety issues. The NIH fact sheet describes flushing with nicotinic acid, no flushing with nicotinamide, and liver toxicity at very high intakes of either form; it makes no statement specific to injectable NAD+. Grant 2019 observed no adverse events during the six-hour NAD+ infusion.
How does compounded NAD+ reach a practice?
Through a licensed 503A pharmacy on a patient-specific prescription, as section 503A requires, with the bulk substance made by an FDA-registered establishment and accompanied by a valid certificate of analysis. FDA states that compounded drugs are not FDA approved and that FDA does not verify their safety, effectiveness or quality before marketing. The prescriber decides whether and how the compound is used.

Esta página se ofrece únicamente con fines informativos. No constituye consejo médico, no está destinada a diagnosticar, tratar, curar ni prevenir ninguna enfermedad, y no sustituye el criterio de un profesional con licencia. Consulte a un profesional de la salud antes de actuar sobre cualquier cosa que aquí se afirme. ExaVeyra Sciences es un proveedor y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. Estas referencias informan lo que los ensayos, las revisiones, las etiquetas de los productos y las comunicaciones de la FDA establecen sobre los compuestos que prepara una farmacia 503A asociada, con fines de formación profesional, y no hacen ninguna afirmación sobre la idoneidad de ningún producto para ningún paciente. Cuando esta página trata un producto aprobado por la FDA, rige el etiquetado aprobado y nada de lo aquí expuesto lo modifica. Las preparaciones compuestas son una clase de producto distinta: no son productos farmacéuticos terminados aprobados por la FDA, se preparan bajo la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos contra una prescripción específica para un paciente, y son productos de prescripción suministrados únicamente a profesionales con licencia. Los ingredientes cosméticos que se tratan aquí se describen dentro del marco regulatorio cosmético y no son medicamentos. La decisión de prescribir corresponde al profesional con licencia. Leer el aviso completo

Solo de referencia. No constituye asesoramiento legal ni médico.

El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Leer el aviso completo